| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sangamo Therapeutics Inc (NASDAQ: SGMO)
SGMO Technical Analysis
3
| As on 3rd Jan 2025 SGMO STOCK Price closed @ 1.21 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.67 & Buy for SHORT-TERM with Stoploss of 0.98 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SGMOSTOCK Price
| Open | 1.13 | Change | Price | % |
| High | 1.26 | 1 Day | 0.08 | 7.08 |
| Low | 1.12 | 1 Week | -1.18 | -49.37 |
| Close | 1.21 | 1 Month | -0.69 | -36.32 |
| Volume | 6145106 | 1 Year | -0.22 | -15.38 |
| 52 Week High 2.87 | 52 Week Low 0.30 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| FCUV | 0.96 | 174.29% |
| NVDA | 144.47 | 4.45% |
| QSI | 4.29 | 0.70% |
| CRNC | 19.33 | 143.76% |
| LMDX | 0.02 | 0.00% |
| CYCC | 0.46 | 24.32% |
| LCID | 3.29 | 8.58% |
| TNXP | 0.31 | 0.00% |
| AKTS | 0.04 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SGMO Daily Charts |
SGMO Intraday Charts |
Whats New @ Bazaartrend |
SGMO Free Analysis |
|
|
SGMO Important Levels Intraday
| RESISTANCE | 1.48 |
| RESISTANCE | 1.39 |
| RESISTANCE | 1.34 |
| RESISTANCE | 1.29 |
| SUPPORT | 1.13 |
| SUPPORT | 1.08 |
| SUPPORT | 1.03 |
| SUPPORT | 0.94 |
SGMO Forecast January 2025
| 4th UP Forecast | 2.48 |
| 3rd UP Forecast | 2.07 |
| 2nd UP Forecast | 1.82 |
| 1st UP Forecast | 1.57 |
| 1st DOWN Forecast | 0.85 |
| 2nd DOWN Forecast | 0.6 |
| 3rd DOWN Forecast | 0.35 |
| 4th DOWN Forecast | -0.06 |
SGMO Weekly Forecast
| 4th UP Forecast | 1.60 |
| 3rd UP Forecast | 1.47 |
| 2nd UP Forecast | 1.40 |
| 1st UP Forecast | 1.32 |
| 1st DOWN Forecast | 1.10 |
| 2nd DOWN Forecast | 1.02 |
| 3rd DOWN Forecast | 0.95 |
| 4th DOWN Forecast | 0.82 |
SGMO Forecast2025
| 4th UP Forecast | 6.78 |
| 3rd UP Forecast | 4.99 |
| 2nd UP Forecast | 3.89 |
| 1st UP Forecast | 2.79 |
| 1st DOWN Forecast | -0.37 |
| 2nd DOWN Forecast | -1.47 |
| 3rd DOWN Forecast | -2.57 |
| 4th DOWN Forecast | -4.36 |
Sangamo Therapeutics Inc ( NASDAQ USA Symbol : SGMO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SGMO Business Profile
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California. Address: 7000 Marina Boulevard, Brisbane, CA, United States, 94005
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service